Yahoo Malaysia Web Search

Search results

1. www.nature.com › articles › d41586/024/02121-1Combined COVID–flu vaccines are coming: Moderna jab clears major...

   www.nature.com › articles › d41586/024/02121-1

   • Cached

   Jun 28, 2024 · Pharmaceutical laboratories are researching new applications for mRNA vaccine technology — and Moderna is hoping to integrate COVID-19, influenza and respiratory syncytial virus immunization ...

2. pharmaphorum.com › news › msd-moderna-take-mrna-jab-phase-3MSD, Moderna take mRNA jab into phase 3 for lung cancer

   pharmaphorum.com › news › msd-moderna-take-mrna-jab-phase-3

   • Cached

   6 days ago · MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer...

3. investors.modernatx.com › news › news-detailsModerna And Mitsubishi Tanabe Pharma Corporation Enter Joint...

   investors.modernatx.com › news › news-details

   • Cached

   Jul 8, 2024 · Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan.

4. Top stories

   • 

     Is Moderna Stock a Buy?

     Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 billion as of the end of the first quarter -- to fund its programs despite a decline in coronavirus-related sales. So Moderna's shares remain a buy, especially as they remain down from their all-time highs.

     The Motley Fool

     2 days ago

   • MarketWatch

     Moderna Inc. stock rises Monday, still underperforms market

     11 hours ago

   • The Business Journals

     How companies like Moderna, Takeda are riding AI hype

     21 hours ago

   • Benzinga on MSN.com

     Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling

     19 hours ago

   • bovnews

     Analyzing Moderna Inc’s (MRNA) Stock earnings per share and revenue

     HSBC Securities raised the price target for the Moderna Inc (NASDAQ:MRNA) stock from “a Hold” to “a Reduce”. The rating was released on February 26, 2024, according to finviz. The research report from Canaccord Genuity has initiated the stock to ...

     1 day ago

   View all

5. www.reuters.com › business › healthcare-pharmaceuticalsModerna says its RSV shot is 50% effective across a second season

   www.reuters.com › business › healthcare-pharmaceuticals

   Jun 26, 2024 · Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.

6. www.reuters.com › business › healthcare-pharmaceuticalsBird flu concern prompts US to award Moderna $176 million for...

   www.reuters.com › business › healthcare-pharmaceuticals

   Jul 2, 2024 · The U.S. government has awarded $176 million to Moderna to advance development of its bird flu vaccine, the company said on Tuesday, as concerns rise over a multi-state outbreak of H5N1 virus in ...

7. www.wired.com › story › moderna-mrna-vaccine-bird-flu-h5n1US Government Awards Moderna $176 Million for mRNA Bird Flu...

   www.wired.com › story › moderna-mrna-vaccine-bird-flu-h5n1

   Jul 4, 2024 · The US government will pay Moderna $176 million to develop an mRNA vaccine against a pandemic influenza—an award given as the highly pathogenic bird flu virus H5N1 continues to spread widely ...

8. edition.cnn.com › 2024/07/02 › healthUS government inks a deal with Moderna to make pandemic flu...

   edition.cnn.com › 2024/07/02 › health

   • Cached

   Jul 2, 2024 · The new $176 million contract with Moderna will help the government stay “nimble” in case it needs to act quickly against any kind of circulating strains of a pandemic flu virus, officials said.